Overview Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients Status: Not yet recruiting Trial end date: 2024-03-31 Target enrollment: Participant gender: Summary The safety and efficacy of CN128 is studied in thalassaemia with sever liver iron overloaded patients. Phase: Phase 2 Details Lead Sponsor: Hangzhou Zede Pharma-Tech Co., Ltd.